| Gene |
PSMB8 |
| UniProt |
P28062 |
| Alternative Names |
LMP7, β5i, Proteasome subunit beta type-8 |
| Molecular Weight |
30.3 kDa |
| Subcellular Localization |
Cytoplasm, Nucleus |
| Protein Family |
Immunoproteasome beta-type subunit |
Psmb8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PSMB8 (Proteasome Subunit Beta Type-8), also known as LMP7 (Low Molecular Mass Protein 7), is a key component of the immunoproteasome. It is encoded by the PSMB8 gene (NCBI Gene ID: 5696) and UniProt ID P28062.[1]
The immunoproteasome is a specialized form of the proteasome that is constitutively expressed in immune cells and induced in neurons and glial cells under inflammatory conditions. PSMB8 forms the catalytic core of the immunoproteasome and is responsible for cleavage of hydrophobic and basic residues from peptide substrates.[2]
PSMB8 is a 276-amino acid protein that undergoes post-translational processing to form the mature catalytic subunit.
The protein adopts the classic Ntn-hydrolase fold, with:
- A catalytic threonine residue (Thr1) at the N-terminus
- A β-sheet dominated core
- Surrounding α-helices
The active site contains a nucleophilic threonine that performs proteolysis through a serine protease-like mechanism.[3]
PSMB8 is incorporated into the 20S immunoproteasome complex as a β-subunit. The mature immunoproteasome consists of:
- Four stacked heptameric rings (α7β7β7α7)
- Two outer α-rings (made of 7 different α-subunits)
- Two inner β-rings (containing PSMB8, PSMB9, PSMB10 as catalytic subunits)
The primary function of PSMB8 is proteolytic degradation of proteins:
- Protein Quality Control: Degradation of misfolded, damaged, or oxidized proteins
- Regulated Proteolysis: Processing of transcription factors, cell cycle regulators, and signaling proteins
- Antigen Processing: Generation of peptide fragments for MHC class I presentation
PSMB8 prefers cleavage after hydrophobic and basic residues (trypsin-like activity), which is distinct from the constitutive proteasome subunits (β5, β1, β2).[4]
- Constitutive Expression: Immune cells (lymphocytes, monocytes, dendritic cells)
- Inducible Expression: Induced in neurons, astrocytes, and microglia by IFN-γ, TNF-α, and other inflammatory cytokines
- Brain Expression: Highest in regions with active protein turnover and synaptic plasticity
PSMB8 and the immunoproteasome are upregulated in AD brain:
- Amyloid-β Processing: Altered immunoproteasome activity affects Aβ generation and clearance
- Tau Pathology: Regulates tau degradation and phosphorylation state
- Neuroinflammation: Drives chronic inflammatory responses
- Synaptic Dysfunction: Affects degradation of synaptic proteins
The constitutive proteasome shows reduced activity in AD, while immunoproteasome activity increases, suggesting a compensatory mechanism that may become maladaptive.[5]
In PD models:
- α-Synuclein Clearance: Immunoproteasome contributes to pathological α-syn degradation
- Mitochondrial Quality Control: Regulates PINK1/Parkin pathway components
- Dopaminergic Neuron Vulnerability: Alters protein homeostasis in susceptible neurons
- Neuroinflammation: Amplifies microglial activation
- TDP-43 Metabolism: Regulates aggregation and clearance of TDP-43
- SOD1 Degradation: Processes mutant SOD1 aggregates
- RNA Metabolism: Affects C9orf72 dipeptide repeat degradation
- Myelin Antigen Presentation: Critical for immune-mediated demyelination
- Oligodendrocyte Death: Contributes to oligodendrocyte degeneration
- Remyelination Failure: Impairs clearance of myelin debris
-
Proteasome Inhibitors:
- Bortezomib (Velcade) - approved for multiple myeloma
- Carfilzomib (Kyprolis) - second-generation inhibitor
-
Selective Immunoproteasome Inhibitors:
- ONX 0914 (PR-957) - selective for LMP7
- IPSI-001 - preferentially inhibits immunoproteasome
-
Neurodegeneration Applications:
- Reducing neuroinflammation
- Modulating antigen presentation
- Altering amyloid/tau clearance
- Systemic immunosuppression risk
- Blood-brain barrier penetration
- Compensatory mechanisms in neurons
- Balance between reducing inflammation and impairing protein clearance
PSMB8 interacts with:
- Other Proteasome Subunits: PSMA1-7 (α-rings), PSMB1-7, PSMB9, PSMB10 (β-rings)
- PA28α/β (11S Regulators): Immunoproteasome assembly and activation
- PA200: Proteasome activator
- Ubiquitin Conjugates: Ubc4, Ubc5
- Chaperones: Hsp90, TRiC/CCT
| Variant |
Effect |
Disease Association |
| rs2736198 |
Promoter variant |
Altered expression in AD |
| rs2305450 |
Coding variant |
Modified MS risk |
| rs35752030 |
Rare variant |
Possible protective in PD |
- IFN-γ treated neurons
- Aβ-stimulated microglia
- Patient-derived iPSC neurons
- PSMB8 knockout mice
- Transgenic AD models with PSMB8 manipulation
The study of Psmb8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Glickman MH. The proteasome and protein homeostasis. Cell. 2002
- Kloetzel PM. The immunoproteasome. Nat Rev Immunol. 2001
- Lowe J. Crystal structure of the 20S proteasome. Nature. 1995
- Groll M. Structure of 20S immunoproteasome. Mol Cell. 2000
- Liang WS. Proteasome impairment in Alzheimer's disease. J Neurosci. 2012
- McCarthy JJ. The immunoproteasome in neurodegeneration. Antioxid Redox Signal. 2013
- Letz S. Immunoproteasome in Parkinson's disease. Mol Neurodegener. 2015